Spaulding Clinical Research, LLC, a Phase 1 Clinical Pharmacology Research Unit and Core ECG Lab announced today that renovation of the clinic's second floor, which was completed on Aug. 20, has made Spaulding Clinical the largest provider of Mortara Surveyor telemetry-monitoring capability in the clinical research world.
“Being the largest telemetry site in the world will continue to help Spaulding Clinical differentiate its service offering from other clinical trial facilities”
Since its inception, Spaulding Clinical has conducted its centralized cardiac safety studies on the third floor of its facility consisting of 48 fully functional telemetry beds. With the opening of the second floor, Spaulding Clinical has doubled its telemetry capacity to 96 beds and has increased its overall operational capacity to 105 beds.
"Since opening our doors in 2008 we have had plans to expand our operations to the second floor of our facility," said Randy Spaulding, founder and CEO of Spaulding Clinical. "Due to the increased demand and acceptance of our unique and innovative model for conducting clinical trials, we absolutely had to expand our operations to meet this significant increase in demand. In fact, we have already begun discussions on our next expansion project which will add 80 more telemetry beds."
By adding the second floor to its operations and beginning plans for future expansion, Spaulding Clinical will continue to attract an increasing number of major pharmaceutical companies to West Bend for their clinical trial needs.
"Being the largest telemetry site in the world will continue to help Spaulding Clinical differentiate its service offering from other clinical trial facilities," said Daniel Selness, Spaulding Clinical's Vice President of Clinical Operations. "This is a very exciting time for our organization and because of the organic growth we are experiencing, we are much better suited to serve the clinical trial needs of pharmaceutical companies throughout the world, big and small."